business-agreement-300x133Discuva Ltd, the antibiotics drug discovery and development company, has announced that its collaboration with Roche, originally initiated in February 2014, has been extended to February 2018 under a new contract amendment.

The collaboration is focused on the discovery and development of new antibiotics to treat life-threatening infections caused by multidrug resistant Gram-negative bacteria using Discuva’s proprietary SATItechnology platform. Financial terms of the extension have not been disclosed.

To date, the collaboration has resulted in multiple lead programmes that target Gram-negative pathogenic bacteria currently causing challenging antibiotic-resistant infections. The candidate antibiotics were identified from a phenotypic screening process and triaged using Discuva’s proprietary SATIN technology to identify compounds with the optimal profile to progress successfully to the next stage of development.

The collaboration extension allows the combined Roche/Discuva team to continue exploring these compounds to expedite the development of these novel antibiotic chemotypes towards essential medicines.

“This contract amendment enables the programmes to benefit from the exceptional input of both parties and move the programmes more efficiently towards patients,” stated Dr David Williams, CEO of Discuva. “We are passionately committed to establishing a succession of novel antibiotics to meet the challenge that the growing threat of antimicrobial resistance represents.”

In February 2014, Discuva and Roche entered into a worldwide collaboration and license agreement for the discovery and development of new antibiotics to treat life-threatening infections caused by multi-drug resistant Gram-negative bacteria using Discuva’s proprietary SATIN technology platform.